Quantitative proteomic study of mitoxantrone-resistant NCI-H460 cell-xenograft tumors

Area of Science:

• Proteomics
• Cancer Biology
• Molecular Oncology

Background:

• Mitoxantrone is a chemotherapy agent used for various cancers.
• Acquired resistance to mitoxantrone poses a significant clinical challenge in cancer treatment.
• Understanding the molecular mechanisms of chemoresistance is crucial for developing effective therapies.

Purpose of the Study:

• To investigate the quantitative proteomic differences between mitoxantrone-resistant and wild-type NCI-H460 lung cancer cells in vivo.
• To identify molecular pathways and protein networks associated with mitoxantrone resistance.
• To explore potential therapeutic targets for overcoming chemoresistance in non-small cell lung cancer.

Main Methods:

• Label-free quantitative proteomic approach using mass spectrometry.
• In vivo xenograft tumor models comparing mitoxantrone-resistant (M group) and wild-type (N group) NCI-H460 cells.
• Bioinformatics analysis including pathway enrichment (KEGG) and protein-protein interaction (Cytoscape, k-means clustering).

Main Results:

• 173 proteins were significantly differentially expressed in mitoxantrone-resistant tumors.
• Actin-mediated cell contraction, muscle system processes, and muscle contraction were identified as key biological processes involved in resistance.
• KEGG pathway analysis highlighted the regulation of systemic lupus erythematosus, alcoholism, viral carcinogenesis, and tight junction pathways.
• Three distinct protein clusters were identified through protein-protein interaction analysis.

Conclusions:

• Differential proteomic profiling successfully identified molecular alterations associated with mitoxantrone resistance in NCI-H460 cells.
• Specific biological processes and pathways are implicated in the development of chemoresistance.
• Further investigation of dysregulated proteins may provide novel strategies to combat chemoresistance in non-small cell lung cancer.